Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28408754 | 0.98 | HRH3 (0.60) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL26329663 | 0.98 | HRH3 (0.60) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL31087909 | 0.98 | HRH3 (0.60) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL8955592 | 0.98 | HRH3 (0.60) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL3345446 | 0.95 | DRD2 (0.58) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL9335578 | 0.94 | HRH3 (0.56) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL6390929 | 0.89 | PPARD (0.53) | HRH3MAPTCRHBPCRHR2DRD2 | |
| SCHEMBL10336454 | 0.89 | PTGS2 (0.62) | HRH3MAPTCRHBPCRHR2KCNH2 | |
| SCHEMBL10336456 | 0.89 | PTGS2 (0.62) | HRH3MAPTCRHBPCRHR2KCNH2 | |
| SCHEMBL9788054 | 0.89 | PTGS2 (0.62) | HRH3MAPTCRHBPCRHR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285777-A1 | INHIBITORS OF TTBK1 | THE GENERAL HOSPITAL CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20070185135-A1 | Drug-Polymer Conjugates | PHARMAESSENTIA CORP. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185135-A1 | Drug-Polymer Conjugates | LNPEP, MSN, ANPEP | HRH3 3304/4885MAPT 1617/4885CRHBP 287/4885 |
| US-20240285777-A1 | INHIBITORS OF TTBK1 | TTBK1, TTBK2, TTK | HRH3 4075/4885MAPT 64/4885CRHBP 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.